The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
Open accessAbstract
Portal hypertension, defined as increased pressure in the portal vein, develops as a consequence of increased intrahepatic vascular resistance due to the dysregulation of liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells (HSCs), frequently arising from chronic liver diseases. Extrahepatic haemodynamic changes contribute to the aggravation of portal hypertension. The pathogenic complexity of portal hypertension and the unsuccessful translation of preclinical studies have impeded the development of effective therapeutics for patients with cirrhosis, while counteracting hepatic and extrahepatic mechanisms also pose a major obstacle to effective treatment. In this review article, we will discuss the following topics: i) cellular and molecular mechanisms of portal hypertension, focusing on dysregulation of LSECs, HSCs and hepatic microvascular thrombosis, as well as changes in the extrahepatic vasculature, since these are the major contributors to portal hypertension; ii) translational/clinical advances in our knowledge of portal hypertension; and iii) future directions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
REVIGO summarizes and visualizes long lists of gene ontology terms
Supek, F., Bošnjak, M., Škunca, N., & Šmuc, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021800 · Cited by 6,264
GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists
Eden, E., Navon, R., Steinfeld, I., Lipson, D., & Yakhini, Z. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-48 · Cited by 3,356
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443 · cited 6×
“Indeed, Rev-erb-alpha also determines the phenotype and behaviour of HSCs.”
BackgroundInfluentialThe Human Gut Microbiome: From Association to Modulation
Schmidt, T. S. B., Raes, J., & Bork, P. (2018) · Cell · doi:10.1016/j.cell.2018.02.044 · Cited by 845 · cited 1×
“years, partly thanks to technological advances in the methods used to investigate the microbiota.(104) Hence, we performed an analysis of the published literature on the gut-liver axis and portal hypertension from the last 15 years and plotted the key”
MethodVillanueva, C., Albillos, A., Genescà, J., Garcia-Pagan, J. C., Calleja, J. L., Aracil, C., Bañares, R., Morillas, R. M., Poca, M., Peñas, B., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31875-0 · Cited by 711 · cited 6×
“In particular, ECM markers may be useful for the detection of CSPH and complications,36,144–146 while inflammatory and haemodynamic markers,147–150 or even circulating miRNA are rather unspecific.151–153 Maybe in the near future, signature molecules based on omics-techniques may help to improve the diagnosis of CSPH.…”
BackgroundInfluentialGut microbiome and liver diseases
Tilg, H., Cani, P. D., & Mayer, E. A. (2016) · Gut · doi:10.1136/gutjnl-2016-312729 · Cited by 525 · cited 1×
“Effects of microbiota on the liver The gut microbiota harbours the largest pool of genetic material in the human body with more than 10(13) microbes with an extremely high metabolic activity.(105,114) Nowadays, there is no doubt that changes in the microbiota influence cirrhosis (summarised in several recent reviews)…”
BackgroundAn Acetylation Site in the Middle Domain of Hsp90 Regulates Chaperone Function
Scroggins, B. T., Robzyk, K., Wang, D., Marcu, M. G., Tsutsumi, S., Beebe, K., Cotter, R. J., Felts, S., Toft, D., Karnitz, L., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.008 · Cited by 413
Abraldes, J. G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., Rodriguez, M., Castellote, J., García-Pagán, J. C., Torres, F., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.004 · Cited by 339
Cited by
Schwabe, R. F., & Brenner, D. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01068-6 · Cited by 112
Thannickal, V. J., Jandeleit‐Dahm, K., Szyndralewiez, C., & Török, N. J. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17649 · Cited by 65
Angiocrine Signaling in Sinusoidal Health and Disease
Cooper, S. A., Kostallari, E., & Shah, V. H. (2023) · Seminars in Liver Disease · doi:10.1055/a-2128-5907 · Cited by 15
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction
Carter, J. K., Tsai, M.-C., Venturini, N., Hu, J., Lemasters, J. J., Torres Martin, M., Sia, D., Wang, S., Lee, Y. A., & Friedman, S. L. (2024) · Hepatology · doi:10.1097/hep.0000000000000782 · Cited by 7
“[2,4] Lowering portal pressures in cirrhosis reduces the risk of life-threatening complications and further hepatic decompensation; however, current therapy with non-selective beta-blockers is limited by extrahepatic effects.”
Wei, N., Du, L., Xiao, Z., Zhang, L., Zhou, Y., Gao, H., Liu, M., Wang, C., Hou, X., Li, Y., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01554-6 · Cited by 3
“There were no signi fi cant differences in liver functional tests (serum ALT, AST and ALB) and collagen deposition (Sirius red staining) between Piezo1 △ EC mice and Piezo1 fl ox/ fl ox mice (Fig.”
Metadata
- Authors
- Iwakiri, Y., & Trebicka, J.
- Venue
- JHEP Reports
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 3
- Issue
- 4
- Pages
- 100316
- ISSN
- 2589-5559 (ISSN-L)
- OpenAlex
- W3169276191
- Cited by
- 220
- References
- 21
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. https://app.cochat.ai/papers/10.1016/j.jhepr.2021.100316
- The paper
- Iwakiri, Y., & Trebicka, J. (2021). Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Reports. https://doi.org/10.1016/j.jhepr.2021.100316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.